Plan af Lowisa stad utgifven 1837 af C. W. Gyldén

Loviisan kartta. - 1 kartta : vär. ; 41 x 55,5 cm, lehti 45 x 60 cm.- Mittakaava [1:8000]. - Sisältää luettelot julkisista paikoista ja rakennuksista sekä toreista ja kaduista.

Plan af Jyväskylä stad utgifven 1840 af C. W. Gyldén

Claes Wilhelm Gyldén (1802-1872) oli maanmittauksen ja metsänhoidon ylihallituksen ylitirehtööri vuosina 1854-72. Ylitirehtööri omisti paljon aikaansa metsänhoidon ja maanjakotoiminnan lisäksi myös maamme kartastotoiminnalle. Hän julkaisi vuonna 1853 Suomenmaan korko-kartan, joka on maailman ensimmäisiä korkeusvyöhykekarttoja. Myös Suomen yleiskartan 1:400 000 (Karta över Finland) ensimmäisen painoksen karttalehdet painettiin vuosina 1864-1872 hänen johtajakaudellaan. Vuosina 1837-1843 toimiessaan maanmittausinsinöörinä maanmittaushallituksessa C. W. Gyldén julkaisi Suomen kaikkien silloisten kaupunkien kaupunkikartat, yhteensä 31 karttalehteä. Nämä asemakaavakartat painettiin kaikki samassa koossa 50,8 x 65,9 cm. Tästä johtuen karttojen mittakaavat vaihtelivat asteikkojen 1:3200 – 1:10000 välillä. Kaupungin asemakaavan lisäksi jokaisessa kartassa on yleissilmäyskartta, julkisten rakennusten luettelo sekä niiden sijainti. Lisäksi hän julkaisi vuonna 1844 näiden kaupunkien historiaa ja tilastotietoja kuvaavan selityskirjan.

Plan af Nycarleby utgifven 1841 af C. W. Gyldén

Uusikaarlepyyn kartta. 1 kartta : vär. ; 40,9 x 54,9 cm, lehti 45 x 60 cm. - Sisältää luettelon julkisista rakennuksista. - Mittakaava: [1:3200]

Plan af Raumo utgifven 1841 af C. W. Gyldén

Rauman kartta. - 1 kartta : vär. ; 40,7 x 54,4 cm, lehti 45 x 60 cm. - Mittakaava [1:4000]. - Sisältää luettelon julkisista rakennuksista.

Plan af Wasa stad utgifven 1839 af C. W. Gyldén

Vaasan kartta. 1 kartta : vär. ; 41 x 55,3 cm, lehti 45 x 60 cm. - Mittakaava: [1:4000]. - Sisältää luettelon julkisista rakennuksista.

Plan af Gamlakarleby utgifven 1838 af C. W. Gyldén

Claes Wilhelm Gyldén (1802-1872) oli maanmittauksen ja metsänhoidon ylihallituksen ylitirehtööri vuosina 1854-72. Ylitirehtööri omisti paljon aikaansa metsänhoidon ja maanjakotoiminnan lisäksi myös maamme kartastotoiminnalle. Hän julkaisi vuonna 1853 Suomenmaan korko-kartan, joka on maailman ensimmäisiä korkeusvyöhykekarttoja. Myös Suomen yleiskartan 1:400 000 (Karta över Finland) ensimmäisen painoksen karttalehdet painettiin vuosina 1864-1872 hänen johtajakaudellaan. Vuosina 1837-1843 toimiessaan maanmittausinsinöörinä maanmittaushallituksessa C. W. Gyldén julkaisi Suomen kaikkien silloisten kaupunkien kaupunkikartat, yhteensä 31 karttalehteä. Nämä asemakaavakartat painettiin kaikki samassa koossa 50,8 x 65,9 cm. Tästä johtuen karttojen mittakaavat vaihtelivat asteikkojen 1:3200 – 1:10000 välillä. Kaupungin asemakaavan lisäksi jokaisessa kartassa on yleissilmäyskartta, julkisten rakennusten luettelo sekä niiden sijainti. Lisäksi hän julkaisi vuonna 1844 näiden kaupunkien historiaa ja tilastotietoja kuvaavan selityskirjan.

A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias

R,S-sotalol, a ß-blocker drug with class III antiarrhythmic properties, is prescribed to patients with ventricular, atrial and supraventricular arrhythmias. A simple and sensitive method based on HPLC-fluorescence is described for the quantification of R,S-sotalol racemate in 500 µl of plasma. R,S-sotalol and its internal standard (atenolol) were eluted after 5.9 and 8.5 min, respectively, from a 4-micron C18 reverse-phase column using a mobile phase consisting of 80 mM KH2PO4, pH 4.6, and acetonitrile (95:5, v/v) at a flow rate of 0.5 ml/min with detection at lex = 235 nm and lem = 310 nm, respectively. This method, validated on the basis of R,S-sotalol measurements in spiked blank plasma, presented 20 ng/ml sensitivity, 20-10,000 ng/ml linearity, and 2.9 and 4.8% intra- and interassay precision, respectively. Plasma sotalol concentrations were determined by applying this method to investigate five high-risk patients with atrial fibrillation admitted to the Emergency Service of the Medical School Hospital, who received sotalol, 160 mg po, as loading dose. Blood samples were collected from a peripheral vein at zero, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0 and 24.0 h after drug administration. A two-compartment open model was applied. Data obtained, expressed as mean, were: CMAX = 1230 ng/ml, TMAX = 1.8 h, AUCT = 10645 ng h-1 ml-1, Kab = 1.23 h-1, a = 0.95 h-1, ß = 0.09 h-1, t(1/2)ß = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg. A good systemic availability and a fast absorption were obtained. Drug distribution was reduced to the same extent in terms of total body clearance when patients and healthy volunteers were compared, and consequently elimination half-life remained unchanged. Thus, the method described in the present study is useful for therapeutic drug monitoring purposes, pharmacokinetic investigation and pharmacokinetic-pharmacodynamic sotalol studies in patients with tachyarrhythmias.

Residual ß-cell function and microvascular complications in type 1 diabetic patients

To determine the influence of residual ß-cell function on retinopathy and microalbuminuria we measured basal C-peptide in 50 type 1 diabetic outpatients aged 24.96 ± 7.14 years, with a duration of diabetes of 9.1 ± 6.2 years. Forty-three patients (86%) with low C-peptide (<0.74 ng/ml) had longer duration of diabetes than 7 patients (14%) with high C-peptide (³0.74 ng/ml) (9 (2-34) vs 3 (1-10) years, P = 0.01) and a tendency to high glycated hemoglobin (HBA1) (8.8 (6-17.9) vs 7.7 (6.9-8.7)%, P = 0.08). Nine patients (18%) had microalbuminuria (two out of three overnight urine samples with an albumin excretion rate (AER) ³20 and <200 µg/min) and 13 (26%) had background retinopathy. No association was found between low C-peptide, microalbuminuria and retinopathy and no difference in basal C-peptide was observed between microalbuminuric and normoalbuminuric patients (0.4 ± 0.5 vs 0.19 ± 0.22 ng/ml, P = 0.61) and between patients with or without retinopathy (0.4 ± 0.6 vs 0.2 ± 0.3 ng/ml, P = 0.43). Multiple regression analysis showed that duration of diabetes (r = 0.30, r2 = 0.09, P = 0.031) followed by HBA1 (r = 0.41, r2 = 0.17, P = 0.01) influenced basal C-peptide, and this duration of diabetes was the only variable affecting AER (r = 0.40, r2 = 0.16, P = 0.004). In our sample of type 1 diabetic patients residual ß-cell function was not associated with microalbuminuria or retinopathy.

Anxiolytic-like effects of 4-phenyl-2-trichloromethyl-3H-1,5-benzodiazepine hydrogen sulfate in mice

The pharmacological effects of 4-phenyl-2-trichloromethyl-3H-1,5-benzodiazepine hydrogen sulfate (PTMB), a novel synthetic benzodiazepine, were examined in mice. In the elevated plus-maze test of anxiety, 0.3-1 mg/kg diazepam ip (F(3,53) = 3.78; P<0.05) and 1-10 mg/kg PTMB ip increased (F(5,98) = 3.26; P<0.01), whereas 2 mg/kg picrotoxin ip decreased (F(3,59) = 8.32; P<0.001) the proportion of time spent in the open arms, consistent with an anxiolytic action of both benzodiazepines, and an anxiogenic role for picrotoxin. In the holeboard, 1.0 mg/kg diazepam ip increased (F(3,54) = 2.78; P<0.05) and 2 mg/kg picrotoxin ip decreased (F(3,59) = 4.69; P<0.01) locomotor activity. Rotarod assessment revealed that 1 mg/kg diazepam ip and 3, 10 and 30 mg/kg PTMB ip produced significant motor incoordination compared to vehicle control (F(4,70) = 7.6; P<0.001). These data suggest that the recently synthesized PTMB compound possesses anxiolytic activity and produces motor incoordination similar to those observed with diazepam.

c-Fos expression induced by electroacupuncture at the Zusanli point in rats submitted to repeated immobilization

In laboratory animals, acupuncture needs to be performed on either anesthetized or, if unanesthetized, restrained subjects. Both procedures up-regulate c-Fos expression in several areas of the central nervous system, representing therefore a major pitfall for the assessment of c-Fos expression induced by electroacupuncture. Thus, in order to reduce the effect of acute restraint we used a protocol of repeated restraint for the assessment of the brain areas activated by electroacupuncture in adult male Wistar rats weighing 180-230 g. Repeated immobilization protocols (6 days, 1 h/day and 13 days, 2 h/day) were used to reduce the effect of acute immobilization stress on the c-Fos expression induced by electroacupuncture at the Zusanli point (EA36S). Animals submitted to immobilization alone or to electroacupuncture (100 Hz, 2-4 V, faradic wave) in a non-point region were compared to animals submitted to electroacupuncture at EA36S (4 animals/subgroup). c-Fos expression was measured in 41 brain areas by simple counting of cells and the results are reported as number of c-Fos-immunoreactive cells/10,000 µm². The protocols of repeated immobilization significantly reduced the immobilization-induced c-Fos expression in most of the brain areas analyzed (P < 0.05). Animals of the EA36S groups had significantly higher levels of c-Fos expression in the dorsal raphe nucleus, locus coeruleus, posterior hypothalamus and central medial nucleus of the thalamus. Furthermore, the repeated immobilization protocols intensified the differences between the effects of 36S and non-point stimulation in the dorsal raphe nucleus (P < 0.05). These data suggest that high levels of stress can interact with and mask the evaluation of specific effects of acupuncture in unanesthetized animals.

HIV-1 binding and neutralizing antibodies of injecting drug users

Previous studies have demonstrated a stronger seroreactivity against some synthetic peptides responsible for inducing neutralizing antibodies in injecting drug users (IDU) compared to that of individuals sexually infected with HIV-1 (S), but the effectiveness in terms of the neutralizing ability of these antibodies has not been evaluated. Our objective was to study the humoral immune response of IDU by determining the specificity of their antibodies and the presence of neutralizing antibodies. The neutralization capacity against the HIV-1 isolate MN (genotype B), the primary HIV-1 isolate 95BRRJ021 (genotype F), and the seroreactivity with peptides known to induce neutralizing antibodies, from the V2 and V3 loops of different HIV-1 subtypes, were analyzed. Seroreactivity indicates that IDU plasma are more likely to recognize a broader range of peptides than S plasma, with significantly higher titers, especially of V3 peptides. Similar neutralization frequencies of the MN isolate were observed in plasma of the IDU (16/47) and S (20/60) groups in the 1:10 dilution. The neutralization of the 95BRRJ021 isolate was more frequently observed for plasma from the S group (15/23) than from the IDU group (15/47, P = 0.0108). No correlation between neutralization and seroreactivity with the peptides tested was observed. These results suggest that an important factor responsible for the extensive and broad humoral immune response observed in IDU is their infection route. There was very little difference in neutralizing antibody response between the IDU and S groups despite their differences in seroreactivity and health status.

Sleep deprivation reduces the lymphocyte count in a non-obese mouse model of type 1 diabetes mellitus

The objective of the present study was to determine whether sleep deprivation (SD) would promote changes in lymphocyte numbers in a type 1 diabetes model (non-obese diabetic, NOD, mouse strain) and to determine whether SD would affect female and male NOD compared to Swiss mice. The number of lymphocytes in peripheral blood after 24 and 96 h of SD (by multiple platform method) or equivalent period of time in home-cage controls was examined prior to the onset of diabetes. SD for 96 h significantly reduced lymphocytes in male Swiss mice compared to control (8.6 ± 2.1 vs 4.1 ± 0.7 10³/µL; P < 0.02). In male NOD animals, 24- and 96-h SD caused a significant decrease of lymphocytes compared to control (4.4 ± 0.3 vs 1.6 ± 0.5; P < 0.001 and 4.4 ± 0.3 vs 0.9 ± 0.1 10³/µL; P < 0.00001, respectively). Both 24- and 96-h SD induced a reduction in the number of lymphocytes in female Swiss (7.5 ± 0.5 vs 4.5 ± 0.5, 4.4 ± 0.6 10³/µL; P < 0.001, respectively) and NOD mice (4 ± 0.6 vs 1.8 ± 0.2, 1.2 ± 0.4 10³/µL; P < 0.01, respectively) compared to the respective controls. Loss of sleep induced lymphopenia in peripheral blood in both genders and strains used. Since many cases of autoimmunity present reduced numbers of lymphocytes and, in this study, it was more evident in the NOD strain, our results suggest that SD should be considered a risk factor in the onset of autoimmune disorders.

Pirkanmaan arvokkaiden harjualueiden inventoinnin tarkistus 2014 : Pohjaveden suojelun ja kiviaineshuollon yhteensovittaminen Pirkanmaalla (POSKI-hanke)

Suomen harjumuodostumat ovat syntyneet Pohjois-Euroopan peittäneen mannerjäätikön reunan perääntymisen yhteydessä noin 10 000 vuotta sitten. Ainutkertaisia harjumuodostumia ei synny uusia ennen seuraavaa jääkautta. Harjuihin liittyy myös erityisiä muutoksille herkkiä elinympäristöjä, kuten paahderinteitä. Viimeisten sadan vuoden aikana ihmisen toiminta on alkanut vaikuttaa harjuihin, joihin kohdistuu nykyään erilaisia ja usein keskenään ristiriitaisia maankäyttöpaineita. Kaikkein voimakkaimmin harjuihin on vaikuttanut (ja vaikuttaa edelleen) maa-ainesten ottaminen, minkä myötä menetetään harjujen geologisia, biologisia ja maisemallisia arvoja. Pirkanmaan arvokkaimmat harjualueet, kuten myös suurimmat hiekka- ja soravarat, sijoittuvat Ikaalisista Tampereen kautta Pälkäneelle kulkevaan saumamuodostumajaksoon sekä Hämeenkyröstä Ruovedelle ja edelleen Mänttä-Vilppulan suuntaan kulkevaan Sisä-Suomen reunamuodostuman varrelle. Harjumuodostumien kartoitus ja inventointi on Suomessa aloitettu valtakunnallisella tasolla 1970-luvulla, ja maa-aineslain tultua voimaan 1980-luvulla rajattiin valtakunnalliseen harjujensuojeluohjelmana liitettävät harjualueet. Tämän jälkeen harjualueiden inventointityötä on tehty paikallisella tasolla maakunnissa. Arvokkaiden harjualueiden rajausten tavoitteena on säilyttää harjujen luonteenomaiset, geologiset, geomorfologiset, biologiset ja maisemalliset piirteet. Samalla pyritään säilyttämään muitakin erityisarvoja, kuten moninais- ja virkistyskäyttöarvoja. Pirkanmaan arvokkaiden harjujen rajauksista on laadittu kolme erilaista selvitystä vuosina 1990–2008. Lisäksi Pirkanmaan 1. maakuntakaavassa on esitetty omat rajauksensa geologisesti arvokkaille harjumuodostumille (ge1-alueet). Jokaisen selvityksen yhteydessä harjualueet (tai osa niistä) on rajattu uudelleen ja tuloksena on syntynyt useita keskenään ristiriitaisia rajauksia. Ongelmia syntyy, kun eri tahot tekevät päätöksiä käyttäen eri aikoina tehtyjä rajauksia. Tämän päivitystyön tavoitteena onkin tarkastella eri aikoina tehtyjen rajausten aiheuttama ristiriitoja ja luoda kaikille alueille uudet, yhtenäisiin kriteereihin perustuvat rajaukset. Tämän työn yhteydessä käytiin läpi kaikki 139 Pirkanmaalle sijoittuvaa arvokkaan harjualueen rajausta. Työssä käytettiin samaa arvoluokitusta (valtakunnallinen, maakunnallinen, paikallinen), kuin alkuperäisessä, vuonna 1990 julkaistussa Pirkanmaan harjuluonto -selvityksessä. Eniten ristiriitoja ja rajausmuutostarpeita esiintyi alueilla, joilla on harjoitettu maa-ainesten ottamista. Varsinaisten rajausmuutosten lisäksi tehtiin muutamia arvoluokitusmuutoksia, kolme aluetta poistettiin arvokkaiden alueiden joukosta kokonaan ja aineistoa täydennettiin neljällä uudella, aiemmin rajaamattomalla alueella. Arvokkaiden harjualueiden rajausten inventoinnin tarkistustyö on osa Pirkanmaalla vuosina 2012–2015 toteutettua pohjavesien suojelun ja kiviaineshuollon yhteensovittamishanketta (POSKI), joka on jatkoa osassa Pirkanmaata vuosina 1997–2000 toteutetulle POSKI-hankkeelle.

Transient high-level expression of ß-galactosidase after transfection of fibroblasts from GM1 gangliosidosis patients with plasmid DNA

GM1 gangliosidosis is an autosomal recessive disorder caused by the deficiency of lysosomal acid hydrolase ß-galactosidase (ß-Gal). It is one of the most frequent lysosomal storage disorders in Brazil, with an estimated frequency of 1:17,000. The enzyme is secreted and can be captured by deficient cells and targeted to the lysosomes. There is no effective treatment for GM1 gangliosidosis. To determine the efficiency of an expression vector for correcting the genetic defect of GM1 gangliosidosis, we tested transfer of the ß-Gal gene (Glb1) to fibroblasts in culture using liposomes. ß-Gal cDNA was cloned into the expression vectors pSCTOP and pREP9. Transfection was performed using 4 µL lipofectamine 2000 and 1.5-2.0 µg DNA. Cells (2 x 10(5)/well) were harvested 24 h, 48 h, and 7 days after transfection. Enzyme specific activity was measured in cell lysate and supernatant by fluorometric assay. Twenty-four hours after transfection, treated cells showed a higher enzyme specific activity (pREP9-ß-Gal: 621.5 ± 323.0, pSCTOP-ß-Gal: 714.5 ± 349.5, pREP9-ß-Gal + pSCTOP-ß-Gal: 1859.0 ± 182.4, and pREP9-ß-Gal + pTRACER: 979.5 ± 254.9 nmol·h-1·mg-1 protein) compared to untreated cells (18.0 ± 3.1 for cell and 32.2 ± 22.2 nmol·h-1·mg-1 protein for supernatant). However, cells maintained in culture for 7 days showed values similar to those of untreated patients. In the present study, we were able to transfect primary patients' skin fibroblasts in culture using a non-viral vector which overexpresses the ß-Gal gene for 24 h. This is the first attempt to correct fibroblasts from patients with GM1 gangliosidosis by gene therapy using a non-viral vector.

Utility of a novel risk score for prediction of ventricular tachycardia and cardiac death in chronic Chagas disease - the SEARCH-RIO study

The SEARCH-RIO study prospectively investigated electrocardiogram (ECG)-derived variables in chronic Chagas disease (CCD) as predictors of cardiac death and new onset ventricular tachycardia (VT). Cardiac arrhythmia is a major cause of death in CCD, and electrical markers may play a significant role in risk stratification. One hundred clinically stable outpatients with CCD were enrolled in this study. They initially underwent a 12-lead resting ECG, signal-averaged ECG, and 24-h ambulatory ECG. Abnormal Q-waves, filtered QRS duration, intraventricular electrical transients (IVET), 24-h standard deviation of normal RR intervals (SDNN), and VT were assessed. Echocardiograms assessed left ventricular ejection fraction. Predictors of cardiac death and new onset VT were identified in a Cox proportional hazard model. During a mean follow-up of 95.3 months, 36 patients had adverse events: 22 new onset VT (mean±SD, 18.4±4‰/year) and 20 deaths (26.4±1.8‰/year). In multivariate analysis, only Q-wave (hazard ratio, HR=6.7; P<0.001), VT (HR=5.3; P<0.001), SDNN<100 ms (HR=4.0; P=0.006), and IVET+ (HR=3.0; P=0.04) were independent predictors of the composite endpoint of cardiac death and new onset VT. A prognostic score was developed by weighting points proportional to beta coefficients and summing-up: Q-wave=2; VT=2; SDNN<100 ms=1; IVET+=1. Receiver operating characteristic curve analysis optimized the cutoff value at >1. In 10,000 bootstraps, the C-statistic of this novel score was non-inferior to a previously validated (Rassi) score (0.89±0.03 and 0.80±0.05, respectively; test for non-inferiority: P<0.001). In CCD, surface ECG-derived variables are predictors of cardiac death and new onset VT.